Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis

Next Previous
X
Search
Trial Profile

A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen; Bausch Health Companies

    • Most Recent Events

    • 23 Mar 2020 Results summarizing malignancy rates in psoriasis clinical studies of brodalumab (NCT00975637; NCT01101100; NCT01708590 (AMAGINE-1); NCT01708603 (AMAGINE-2); NCT01708629 (AMAGINE-3).) published in the American Journal of Clinical Dermatology
    • 06 Sep 2019 Protocol has been amended at week 123 that allowed patients with an inadequate response during treatment with brodalumab 140 mg Q2W to have their dose increased to 210 mg Q2W, according to results published in the American Journal of Clinical Dermatology.
    • 06 Sep 2019 Results published in the American Journal of Clinical Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top